Carcinosarcoma
Therapeutic area
Oncology
Rare disease
No
- Definition
- A malignant tumor composed of a mixture of carcinomatous and sarcomatous elements.
- Genetic basis
- No
- Non-human condition
- No
- Rare disease
- No
- Listing at source
- Listed
- Condition name
- Carcinosarcoma
- Therapeutic area
- Oncology
- carcinosarcoma
- carcinosarcoma, malignant
- malignant mixed mesodermal (mullerian) tumour
- malignant mixed Mullerian tumour
- mesodermal mixed tumor (morphologic abnormality)
- mesodermal mixed tumour
- mesodermal mixed tumour (morphologic abnormality)
- mixed mesodermal (mullerian) tumour
- mullerian mixed tumor (morphologic abnormality)
- mullerian mixed tumour
- mullerian mixed tumour (morphologic abnormality)
- mixed Mullerian tumor
- mixed Mullerian tumour
- mixed tumor, Mullerian
- All therapeutic areas
- Oncology
Sources for recorded values
- Severity
- Severe
- MONDO ID
- MONDO:0002928
- Parent condition
- MONDO:0005853
Related records
Broader conditions (9)
- Cancer
- Cancer or benign tumor
- Disease
- Disease by etiologic mechanism
- Human disease
- Malignant mixed neoplasm
- Mixed neoplasm
- Neoplasm
- Neoplastic disease or syndrome
Narrower conditions (5)
- Carcinosarcoma of the corpus uteri
- Cervical carcinosarcoma
- Fallopian tube carcinosarcoma
- Ovarian carcinosarcoma
- Uterine carcinosarcoma
Trials (64)
- (VELA) Study of BLU-222 in Advanced Solid Tumors
- A Blended e-Health Intervention to Improve Fear of Progression in Women With Gynecologic or Breast Cancer
- A Phase 1b/2 Study of Rebastinib (DCC-2036) in Combination With Paclitaxel in Patients With Advanced or Metastatic Solid Tumors
- A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer
- A Study of DKN-01 as a Monotherapy or in Combination With Paclitaxel in Patients With Recurrent Epithelial Endometrial or Epithelial Ovarian Cancer or Carcinosarcoma
- A Study of INCB099280 in Combination With Axitinib in Adults With Advanced Solid Tumors
- A Study of Nivolumab in Selected Uterine Cancer Patients
- A Study of PHST001 in Advanced Solid Tumors
- A Study to Evaluate Rucaparib in Participants With Solid Tumors and With Deleterious Mutations in HRR Genes
- Adjuvant Radiation Therapy With Ifosfamide in Patients With Mixed Mesodermal Tumors of the Uterus
- Agnostic Therapy in Rare Solid Tumors
- APL-2 and Pembrolizumab Versus APL-2, Pembrolizumab and Bevacizumab Versus Bevacizumab Alone for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer and Malignant Effusion
- Assessment of Compliance With Monitoring Conducted by a Physician in Person or by a Nurse in Remote Monitoring
- ATr Inhibitor in Combination With Olaparib/Durvalumab (MEDI4736) in Gynaecological Cancers With ARId1A Loss or no Loss
- Cabozantinib S-malate and Nivolumab in Treating Patients With Advanced, Recurrent, or Metastatic Endometrial Cancer
- Camrelizumab Combined With Apatinib in the Treatment of Advanced Sarcomatoid Carcinoma or Carcinosarcoma
- Carboplatin and Paclitaxel in Elderly Women With Newly Diagnosed Ovarian, Peritoneal, or Fallopian Cancer
- Carboplatin and Paclitaxel With or Without Bevacizumab Compared to Docetaxel, Carboplatin, and Paclitaxel in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Carcinoma (Cancer)
- Carboplatin, Paclitaxel, and Pegfilgrastim in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Fallopian Tube, Primary Peritoneal, or Carcinosarcoma Cancer
- Carboplatin, Paclitaxel, Bevacizumab, and Veliparib in Treating Patients With Newly Diagnosed Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer
Drugs in development (31)
- Cabozantinib Phase 2
- Camrelizumab Phase 2
- Carboplatin Phase 2
- Ceralasertib Phase 2
- Cisplatin Phase 3
- DKN-01 Phase 2
- Dostarlimab Phase 2
- Doxorubicin Phase 2
- Durvalumab Phase 2
- Filgrastim Phase 3
- Ganetespib Phase 2
- Gemcitabine Phase 2
- Ifosfamide Phase 3
- Ipilimumab Phase 2
- Ixabepilone Phase 1
- Lapatinib Phase 1
- Niraparib Phase 2
- Nivolumab Phase 2
- Olaparib Phase 2
- Oxaliplatin Phase 2